P Pharming Group NV
P
Atvērts
1.132 0.44
Pārskats
Akcijas cenas izmaiņa
24h
Min
1.127
Max
1.133
Ienākumi | -10M -5.1M |
|---|---|
Pārdošana | -36M 71M |
P/E Sektora vidējais | 55.5 49.712 |
EPS | -0.006 |
Peļņas marža | -7.196 |
Darbinieki | 407 |
EBITDA | -4.8M -2.1M |
Nākamie ieņēmumi | 2026. g. 30. jūl. |
|---|
Tirgus kapitalizācija | -225M 784M |
|---|---|
Iepriekšējā atvēršanas cena | 0.69 |
Iepriekšējā slēgšanas cena | 1.132 |
Pharming Group NV Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
